Global Guillain-Barré Syndrome Treatment Market 2019-2023

ギラン・バレー症候群治療の世界市場2019-2023

◆タイトル:Global Guillain-Barré Syndrome Treatment Market 2019-2023
◆商品コード:IRTNTR30224
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年11月8日
◆ページ数:111
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥364,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥520,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、ギラン・バレー症候群治療の世界市場について調査・分析し、市場概要、市場環境、ギラン・バレー症候群治療市場規模、製品別(免疫グロブリン、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。

・エグゼクティブサマリー
・調査範囲・調査手法
・ギラン・バレー症候群治療の世界市場概要
・ギラン・バレー症候群治療の世界市場環境
・ギラン・バレー症候群治療の世界市場動向
・ギラン・バレー症候群治療の世界市場規模
・ギラン・バレー症候群治療の世界市場:業界構造分析
・ギラン・バレー症候群治療の世界市場:製品別(免疫グロブリン、その他)
・ギラン・バレー症候群治療の世界市場:地域別市場規模・分析
・ギラン・バレー症候群治療の北米市場規模・予測
・ギラン・バレー症候群治療のヨーロッパ・中東・アフリカ市場規模・予測
・ギラン・バレー症候群治療のアジア太平洋市場規模・予測
・ギラン・バレー症候群治療の主要国分析
・ギラン・バレー症候群治療の世界市場:意思決定フレームワーク
・ギラン・バレー症候群治療の世界市場:成長要因、課題
・ギラン・バレー症候群治療の世界市場:競争環境
・ギラン・バレー症候群治療の世界市場:関連企業情報(ベンダー分析)

109 pages, November 2018
About this market
The trend of strategic alliances to help market grow at a flourishing rate. Pharmaceutical companies are working together for the development of medications for the treatment of Guillain-Barré syndrome. These alliances will enhance the R&D activities of new drugs for the management of Guillain-Barré syndrome. Technavio’s analysts have predicted that the Guillain-Barré syndrome treatment market will register a CAGR of more than 5% by 2023.
Market Overview
Recent approvals of immunoglobulins
Immunoglobulins are the first line treatment of Guillain-Barré syndrome. The recent approvals of novel immunoglobulins from regulatory bodies are expected to propel the growth of the global Guillain-Barré syndrome treatment market during the forecast period.
Availability of alternate therapies
Currently there is no cure for Guillain-Barré syndrome. The goal of the available treatments is to provide relief from the symptoms of disease. Although the intravenous immunoglobin therapy is more convenient and widely available, it has certain side effects. Hence, some physicians are strongly inclined toward other available plasma exchange procedures for the treatment of Guillain-Barré syndrome.
For the detailed list of factors that will drive and challenge the growth of the Guillain-Barré syndrome treatment market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including CSL and Grifols the competitive environment is quite intense. Factors such as the recent approvals of immunoglobulins and strategic alliances, will provide considerable growth opportunities to Guillain-Barré syndrome treatment manufactures. CSL, Grifols, Octapharma, Shire, and Kedrion are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. The market will witness the emergence of many international and regional GBS treatment companies who offer therapeutics such as immunoglobulins and other therapeutics. Pharmaceutical companies are working together for the development of medications for the treatment of Guillain-Barré syndrome, which is expected to enhance the R&D activities of new drugs for the management of GB syndrome.’

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
• PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Immunoglobulins – Market size and forecast 2018-2023
• Other therapeutics – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• CSL
• Grifols
• Kedrion
• Octapharma
• Shire
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global neurological disorder drugs market
Exhibit 02: Segments of global neurological disorder drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Product – Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Immunoglobulins – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Immunoglobulins – Year-over-year growth 2019-2023 (%)
Exhibit 21: Other therapeutics – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Other therapeutics – Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in Americas
Exhibit 30: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in EMEA
Exhibit 33: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in APAC
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: CSL – Vendor overview
Exhibit 45: CSL – Business segments
Exhibit 46: CSL – Organizational developments
Exhibit 47: CSL – Geographic focus
Exhibit 48: CSL – Segment focus
Exhibit 49: CSL – Key offerings
Exhibit 50: CSL – Key customers
Exhibit 51: Grifols – Vendor overview
Exhibit 52: Grifols – Business segments
Exhibit 53: Grifols – Organizational developments
Exhibit 54: Grifols – Geographic focus
Exhibit 55: Grifols – Segment focus
Exhibit 56: Grifols – Key offerings
Exhibit 57: Grifols – Key customers
Exhibit 58: Kedrion – Vendor overview
Exhibit 59: Kedrion – Business segments
Exhibit 60: Kedrion – Organizational developments
Exhibit 61: Kedrion – Geographic focus
Exhibit 62: Kedrion – Segment focus
Exhibit 63: Kedrion – Key offerings
Exhibit 64: Kedrion – Key customers
Exhibit 65: Octapharma – Vendor overview
Exhibit 66: Octapharma – Organizational developments
Exhibit 67: Octapharma – Key offerings
Exhibit 68: Octapharma – Key customers
Exhibit 69: Shire – Vendor overview
Exhibit 70: Shire – Business segments
Exhibit 71: Shire – Organizational developments
Exhibit 72: Shire – Geographic focus
Exhibit 73: Shire – Key offerings
Exhibit 74: Shire – Key customers




【掲載企業】

CSL、Grifols、Kedrion、Octapharma、Shire

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[ギラン・バレー症候群治療の世界市場2019-2023]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆